MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.urology.2026.10.005

Медицинская библиотека · Urology · 2026

Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer.

Tallman Jacob E, Hyman Max J, Agarwal Piyush K, Faris Sarah F, Modi Parth K

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

To characterize the utilization of oral pharmacotherapy and minimally invasive non-pharmacologic treatments approved for overactive bladder among patients receiving intravesical therapy for non-muscle invasive bladder cancer, as this treatment is frequently complicated by lower urinary tract symptoms, which are associated with treatment discontinuation and worse oncological outcomes.

METHODS

We conducted a retrospective cohort study using the Merative™ MarketScan® Commercial Database (2016-2024). We identified patients with bladder cancer receiving intravesical bacillus Calmette-Guérin or chemotherapy. The primary outcome was the receipt of lower urinary tract symptom therapy-oral pharmacotherapy (anticholinergics, β-3 agonists, alpha blockers) or minimally invasive non-pharmacologic treatments (botulinum toxin injection, sacral neuromodulation, percutaneous tibial nerve stimulation)-in the 180 days after initiating induction therapy.

RESULTS

Among 2,978 patients, 29.6% received lower urinary tract symptom therapy. Use of alpha blockers (19.9%) and anticholinergics (13.7%) predominated. Use of β-3 agonists (1.3%) or non-pharmacologic treatments was exceedingly rare: only 0.3% received botulinum toxin injection, and no patients received sacral neuromodulation or percutaneous tibial nerve stimulation. Lower urinary tract symptom therapy was associated with a lower proportion of patients completing induction therapy (75.9% vs. 79.0%) (P=0.049) and higher proportion of patients undergoing cystectomy (14.8% vs. 11.9%) (P=0.021).

CONCLUSIONS

While nearly one-third of bladder cancer patients require pharmacotherapy for lower urinary tract symptoms during intravesical treatment, β-3 agonists and non-pharmacologic treatments are almost entirely unutilized. Given the association between lower urinary tract symptoms and induction therapy non-completion, further research into these advanced therapies is warranted to improve patient adherence and oncologic outcomes.

Для цитирования: Tallman Jacob E, Hyman Max J, Agarwal Piyush K, Faris Sarah F, Modi Parth K. Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer.. Urology. 2026. DOI: 10.1016/j.urology.2026.10.005.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.